29th Mar 2019 09:16
LONDON (Alliance News) - Biopharmaceutical firm Hutchison China MediTech Ltd on Friday said it has begun a study of cancer drug surufatinib in patients with advanced biliary tract cancer.
The biliary tract includes all organs and ducts used by the body to make bile and includes the gallbladder, as well as the bile ducts inside and outside of the liver.
The first patient in the phase 2b/3 study, which is taking place in China, was dosed last Friday. The study will compare surufatinib with the chemotherapy drug capecitabine and its primary endpoint is overall survival.
Secondary outcomes from the trial include tumour control measures such as progression free survival, duration of response, and quality of life.
Hutchison China MediTech said the study complements an early-stage proof-of-concept study in China as well as a phase 1b study in the US that is enrolling patients with biliary tract cancer and pancreatic neuroendocrine tumours.
Shares in Hutchison China MediTech were up 4.7% at 4,686.00 on Friday morning.
Related Shares:
Hutchmed